Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 12

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Dermatomyositis+2

Recruiting

Study on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Pfizer Inc.

Systemic scleroderma

Recruiting

Study on the Safety of T-Guard (Dafsolimab Setaritox, Grisnilimab Setaritox) for Patients with Early Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dafsolimab setaritox
  • Sponsor:Philikos B.V.

Psoriasis

Recruiting

Study on Sodium Fluoride (18F) PET-CT Scans for Detecting Bone Changes in Psoriasis Patients at Risk of Psoriatic Arthritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium fluoride (18F)
  • Sponsor:Amsterdam UMC Stichting

Diabetic foot

Recruiting

Study on the Safety and Effectiveness of Allogenic Stem Cells for Treating Diabetic Foot Ulcers in Patients with Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Medical University Of Warsaw

Diabetic foot+1

Recruiting

Study on the Effects of Autologous Bone Marrow-Derived Mononuclear Cells for Patients with Diabetic Foot Syndrome and Lower Limb Ischemia

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Autologous bone marrow-derived mononuclear cells
  • Sponsor:Institute For Clinical And Experimental Medicine

Basal cell carcinoma

Recruiting

Study Comparing Electrochemotherapy with Bleomycin to Standard Radiotherapy for Treating Basal Cell Carcinoma in Patients with Tumors Less Than 3 cm

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Region Hovedstaden

Tuberous sclerosis complex

Recruiting

Study on the Effects of Full Spectrum Cannabis Extract (Dronabinol, Cannabidiol) for Patients with Hard-to-Treat Epilepsy in Tuberous Sclerosis Complex

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Cannabidiol
  • Sponsor:Oils4cure S.L.

Naevus flammeus

Recruiting

Study on the Effects of Sirolimus Cream for Patients with Port Wine Stains

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Sirolimus
  • Sponsor:Aft Pharmaceuticals Limited

Tuberous sclerosis complex+1

Recruiting

Study on the Safety and Effectiveness of Sirolimus and Vigabatrin for Preventing Symptoms in Infants with Tuberous Sclerosis Complex

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Sirolimus
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Actinic keratosis

Recruiting

Study on the Effectiveness of 5% Potassium Hydroxide Solution for Treating Mild to Moderate Actinic Keratosis in Adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Potassium hydroxide
  • Sponsor:INFECTOPHARM Arzneimittel und Consilium GmbH

Basal cell carcinoma

Recruiting

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Hidradenitis

Recruiting

Study on Botulinum Toxin Type A for Treating Hidradenitis Suppurativa in Patients: A Comparison of Different Drug Combinations

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Frederiksberg Hospital

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.